Tango Therapeutics
TNGX
46 hedge funds and large institutions have $844M invested in Tango Therapeutics in 2021 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 12 closing their positions.
464% more capital invested
Capital invested by funds: $150M → $844M (+$695M)
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
125% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 12
48% more funds holding
Funds holding: 31 → 46 (+15)
13.31% more ownership
Funds ownership: 61.53% → 74.84% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP IV
Boston,
Massachusetts
|
+$232M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$82.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$74.9M |
| 4 |
CC
Casdin Capital
New York
|
+$65.8M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$52.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.69M |
| 2 |
PA
Perceptive Advisors
New York
|
-$5.69M |
| 3 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$4.55M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.82M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$2.28M |
TNGX Hedge Fund Activity: Q3 2021 in Review
46 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q3 2021, worth a combined $844M — up 464% from $150M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new TNGX positions and 12 closed out — a net gain of 15 holders — while 10 added to existing stakes and 4 trimmed.
The largest buyer was TRV GP IV, opening a new position worth an estimated $232M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $5.69M sold.
- 46 institutional investors held Tango Therapeutics (TNGX) as of Q3 2021, up from 31 in Q2 2021.
- Funds reported $844M of Tango Therapeutics stock for Q3 2021, up 464% quarter-over-quarter.
- 27 funds opened new Tango Therapeutics positions in Q3 2021 and 12 closed out, a net change of +15 holders.
- The largest Tango Therapeutics buyer in Q3 2021 was TRV GP IV, an estimated $232M added.
- The largest Tango Therapeutics seller in Q3 2021 was Adage Capital Partners, an estimated $5.69M sold.
Based on aggregated 13F filings for Q3 2021.